...CTX001 is in a Phase I/II trial, while Editas’ EDIT-301 is in preclinical development.FDA approves Merck’s...

...Senior Editor The Phase III miss for Merck...
...can help overcome checkpoint resistance. On Wednesday, Merck...
...of development, said on a Wednesday investor call.Merck...

...autoimmune assets. First up for the company is a Phase IIb-ready Berger disease therapy from Merck...
...area he says is “underserved by science right now.”Vera in-licensed its first program, atacicept, from Merck...
...disease, or IgA nephropathy (IgAN), an orphan chronic kidney disease for which there are no approved therapies. Merck...

...collaborations, including one with the U.K. on COVID-19. Celentano's track record includes vaccine-related roles with Merck...

...$650 million up front and up to $1.6 billion in milestones, plus royalties. Priority review for Merck’s...
...subject to comment. TARGETSSGLT1 – Sodium-glucose cotransporter 1SGLT2 – Sodium-glucose cotransporter 2 BC Staff Lexicon Pharmaceuticals Inc. Bayer AG Merck...

...terminated obicetrapib’s development in 2017 for strategic reasons, not long after a CETP readout from Merck...
...among CETP, LDL-C lowering and CV risk. Moreover, further clinical study of another CETP program, Merck’s...
...events that cardiologists believed would have led them to prescribe the compound over generic ezetimibe; Merck...

...is in a randomized Phase I/II trial in combination with anti-PD-1 mAb Keytruda pembrolizumab from Merck...

...more than 100,000 diverse strains isolated from across the globe and assembled by pharmas including Merck...

...the company as chief safety officer from Merck...
...where he was chief safety officer for Merck...

...activation.”Sanofi is at least the second pharma to enter the myeloid checkpoint space. In September, Merck...